President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाKyle Diamantas 53%
No announcement by December 31 14.3%
Brett Giroir 4.0%
Stephen Hahn 4%
नया
नया
31 दिस, 2026
Kyle Diamantas
53%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
14%
Kyle Diamantas 53%
No announcement by December 31 14.3%
Brett Giroir 4.0%
Stephen Hahn 4%
नया
नया
31 दिस, 2026
Kyle Diamantas
$1,525 वॉल्यूम
53%
Stephen Hahn
$976 वॉल्यूम
4%
Brett Giroir
$1,510 वॉल्यूम
4%
Grace Graham
$1,893 वॉल्यूम
3%
Sara Brenner
$849 वॉल्यूम
3%
No announcement by December 31
$533 वॉल्यूम
14%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 12, 2026, 7:59 PM ET
वॉल्यूम
$7,286समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
वॉल्यूम
$7,286समाप्ति तिथि
31 दिस, 2026बाज़ार खुला
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...President Trump’s recent appointment of Kyle Diamantas as acting FDA commissioner following Marty Makary’s resignation has positioned the FDA deputy commissioner for food as the clear frontrunner in trader assessments for the permanent role. Diamantas assumed acting duties in mid-May 2026 after serving in senior FDA food-policy positions and has received public White House support for advancing administration priorities on food safety and regulatory reform. Other names under active consideration, including former commissioner Stephen Hahn and former acting commissioner Brett Giroir, register lower probabilities consistent with their more limited recent involvement in day-to-day agency operations. The market also prices a meaningful chance of no formal announcement before year-end, reflecting the ongoing search process and typical timelines for Senate-confirmed appointments.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न